Ann: Race Receives $4.0m R&D Tax Refund for Financial Year 2023, page-20

Yes, there is one person with overarching responsibility to ensure resources are deployed for shareholder value during the previous CEO period. $25.7m raised for clinicals (excluding formulations) and $11.0m left allocated to clinicals from remaining cash at the time of last strategy update - pretty poor in my book. Today's half year show $6.1m through R&D expense, when most programs were suspended, so majority is likely these consultants. One can only hope all the invoices were captured pre audit close and this is the last of the "experiment" costs.... possibly not. The "new" CEO seems to have shareholder value as part of his mantra so I am focused on the future from here....